BioLab Holdings Announces Investment in Advanced Synthetic Antimicrobial – Tissue Regeneration Solutions
Summary: January 27, 2026 press release: BioLab Holdings (Phoenix) announces strategic investment in Imbed Biosciences (Wisconsin) for SAM™ Antimicrobial Technology and Microlyte® wound matrix. Microlyte®: fully-synthetic, bioresorbable polymer matrix conforms to wound contours, sustains silver antimicrobial (≥72h), maintains moisture, optimizes surface for cell migration/proliferation. Clinical: accelerated reduction/closure in chronic/non-healing wounds. Investment differentiates BioLab’s portfolio (physician office focus), expands distribution, supports next-gen SAM™ platforms (e.g., pain-management integration). Collaboration ensures integration across outpatient/acute/advanced care; addresses biologic variability/supply issues.
Key Highlights:
- Tech: Synthetic, antimicrobial, regenerative matrix.
- Benefits: Consistent, easy-use, infection reduction, healing support.
- Rationale: Portfolio expansion, commercialization acceleration.
- Relevance: Advances synthetic alternatives for chronic wounds.
Keywords: Microlyte, SAM technology, synthetic antimicrobial, Biolab Imbed